|
1
|
Ohgaki H and Kleihues P: Population-based
studies on incidence, survival rates, and genetic alterations in
astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol.
64:479–489. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fleming TP, Saxena A, Clark WC, Robertson
JT, Oldfield EH, Aaronson SA and Ali IU: Amplification and/or
overexpression of platelet-derived growth factor receptors and
epidermal growth factor receptor in human glial tumors. Cancer Res.
52:4550–4553. 1992.PubMed/NCBI
|
|
3
|
van den Bent MJ, Brandes AA, Rampling R,
Kouwenhoven MC, Kros JM, Carpentier AF, Clement PM, Frenay M,
Campone M, Baurain JF, et al: Randomized phase II trial of
erlotinib versus temozolomide or carmustine in recurrent
glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol.
27:1268–1274. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Harris AL: Hypoxia - a key regulatory
factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Steinbach JP, Klumpp A, Wolburg H and
Weller M: Inhibition of epidermal growth factor receptor signaling
protects human malignant glioma cells from hypoxia-induced cell
death. Cancer Res. 64:1575–1578. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ronellenfitsch MW, Brucker DP, Burger MC,
Wolking S, Tritschler F, Rieger J, Wick W, Weller M and Steinbach
JP: Antagonism of the mammalian target of rapamycin selectively
mediates metabolic effects of epidermal growth factor receptor
inhibition and protects human malignant glioma cells from
hypoxia-induced cell death. Brain. 132:1509–1522. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Düvel K, Yecies JL, Menon S, Raman P,
Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S,
et al: Activation of a metabolic gene regulatory network downstream
of mTOR complex 1. Mol Cell. 39:171–183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
de Groot JF, Fuller G, Kumar AJ, Piao Y,
Eterovic K, Ji Y and Conrad CA: Tumor invasion after treatment of
glioblastoma with bevacizumab: Radiographic and pathologic
correlation in humans and mice. Neuro-oncol. 12:233–242. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Steinbach JP, Supra P, Huang H-JS, Cavenee
WK and Weller M: CD95-mediated apoptosis of human glioma cells:
Modulation by epidermal growth factor receptor activity. Brain
Pathol. 12:12–20. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Steinbach JP, Wolburg H, Klumpp A, Probst
H and Weller M: Hypoxia-induced cell death in human malignant
glioma cells: Energy deprivation promotes decoupling of
mitochondrial cytochrome c release from caspase processing and
necrotic cell death. Cell Death Differ. 10:823–832. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fischer S, Ronellenfitsch MW, Thiepold
A-L, Harter PN, Reichert S, Kögel D, Paschke R, Mittelbronn M,
Weller M, Steinbach JP, et al: Hypoxia enhances the antiglioma
cytotoxicity of B10, a glycosylated derivative of betulinic acid.
PLoS One. 9:e949212014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wanka C, Brucker DP, Bähr O,
Ronellenfitsch M, Weller M, Steinbach JP and Rieger J: Synthesis of
cytochrome C oxidase 2: A p53-dependent metabolic regulator that
promotes respiratory function and protects glioma and colon cancer
cells from hypoxia-induced cell death. Oncogene. 31:3764–3776.
2012. View Article : Google Scholar
|
|
13
|
Wanka C, Steinbach JP and Rieger J:
Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects
glioma cells from starvation-induced cell death by up-regulating
respiration and improving cellular redox homeostasis. J Biol Chem.
287:33436–33446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peereboom DM, Shepard DR, Ahluwalia MS,
Brewer CJ, Agarwal N, Stevens GH, Suh JH, Toms SA, Vogelbaum MA,
Weil RJ, et al: Phase II trial of erlotinib with temozolomide and
radiation in patients with newly diagnosed glioblastoma multiforme.
J Neurooncol. 98:93–99. 2010. View Article : Google Scholar
|
|
15
|
Marcus HJ, Carpenter KLH, Price SJ and
Hutchinson PJ: In vivo assessment of high-grade glioma biochemistry
using microdialysis: A study of energy-related molecules, growth
factors and cytokines. J Neurooncol. 97:11–23. 2010. View Article : Google Scholar
|
|
16
|
Collingridge DR, Piepmeier JM, Rockwell S
and Knisely JP: Polarographic measurements of oxygen tension in
human glioma and surrounding peritumoural brain tissue. Radiother
Oncol. 53:127–131. 1999. View Article : Google Scholar
|
|
17
|
Kim SM, Yun MR, Hong YK, Solca F, Kim J-H,
Kim H-J and Cho BC: Glycolysis inhibition sensitizes non-small cell
lung cancer with T790M mutation to irreversible EGFR inhibitors via
translational suppression of Mcl-1 by AMPK activation. Mol Cancer
Ther. 12:2145–2156. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Faubert B, Boily G, Izreig S, Griss T,
Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, et
al: AMPK is a negative regulator of the Warburg effect and
suppresses tumor growth in vivo. Cell Metab. 17:113–124. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miwa H, Shikami M, Goto M, Mizuno S,
Takahashi M, Tsunekawa-Imai N, Ishikawa T, Mizutani M, Horio T,
Gotou M, et al: Leukemia cells demonstrate a different metabolic
perturbation provoked by 2-deoxyglucose. Oncol Rep. 29:2053–2057.
2013.PubMed/NCBI
|
|
20
|
Liu X, Chhipa RR, Pooya S, Wortman M,
Yachyshin S, Chow LM, Kumar A, Zhou X, Sun Y, Quinn B, et al:
Discrete mechanisms of mTOR and cell cycle regulation by AMPK
agonists independent of AMPK. Proc Natl Acad Sci USA.
111:E435–E444. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Leprivier G, Remke M, Rotblat B, Dubuc A,
Mateo AR, Kool M, Agnihotri S, El-Naggar A, Yu B, Somasekharan SP,
et al: The eEF2 kinase confers resistance to nutrient deprivation
by blocking translation elongation. Cell. 153:1064–1079. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jeon S-M, Chandel NS and Hay N: AMPK
regulates NADPH homeostasis to promote tumour cell survival during
energy stress. Nature. 485:661–665. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qian X, Li J, Ding J, Wang Z, Zhang W and
Hu G: Erlotinib activates mitochondrial death pathways related to
the production of reactive oxygen species in the human non-small
cell lung cancer cell line A549. Clin Exp Pharmacol Physiol.
36:487–494. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao F, Mancuso A, Bui TV, Tong X, Gruber
JJ, Swider CR, Sanchez PV, Lum JJ, Sayed N, Melo JV, et al:
Imatinib resistance associated with BCR-ABL upregulation is
dependent on HIF-1alpha-induced metabolic reprograming. Oncogene.
29:2962–2972. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
De Rosa V, Iommelli F, Monti M, Fonti R,
Votta G, Stoppelli MP and Del Vecchio S: Reversal of Warburg effect
and reactivation of oxidative phosphorylation by differential
inhibition of EGFR signaling pathways in non-small cell lung
cancer. Clin Cancer Res. 21:5110–5120. 2015. View Article : Google Scholar : PubMed/NCBI
|
